Evidence Hub

Exploration of pyrazole-based pyridine-4-carbohydrazide derivatives as drug-resistant Mtb agents: design, synthesis, biological evaluation, and in-silico studies

Kumar P, Malik P, Ali J, Saxena D, Singampalli A, Bandela R, Bellapukonda SM, Rajyalakshmi SI et al.

Future medicinal chemistry, 2025

4 citations

Abstract

Background: Development of new effective drugs against multidrug resistant Mycobacterium tuberculosis is the need of the hour to combat tuberculosis (TB) disease.

Materials and methods: Pyridine-4-carbohydrazide and substituted pyrazole aldehydes were used to synthesize target molecules (6a-r) which were evaluated against H37Rv and drug-resistant TB strains. Time kill kinetics assay was performed to check bactericidal/bacteriostatic effect, molecular docking, dynamics simulation over 100 ns was performed against enoyl acyl carrier protein reductase (InhA) along with QSAR, ADMET profile prediction.

Results: All compounds displayed excellent MICs in the range of 0.125-16 µg/mL. The most potent compound, 6q, with an MIC of 0.125 µg/mL showed bactericidal effect and was effective on ethambutol and streptomycin resistant Mtb strains with an MIC of 0.03 µg/mL and rifampicin resistant Mtb strain with an MIC of 0.25 µg/mL.

Conclusion: The pyrazole clubbed with pyridine-4-carbohydrazide is a potential scaffold for further exploration as anti-TB agent.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free